Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
21
PTCT Quote, Financials, Valuation and Earnings
Last price:
$68.17
Seasonality move
:
-4.69%
Day range:
$67.28 - $69.43
52-week range:
$35.95 - $87.50
Dividend yield:
0%
P/E ratio:
8.81x
P/S ratio:
3.27x
P/B ratio:
--
Volume:
852.2K
Avg. volume:
1.1M
1-year change:
34.84%
Market cap:
$5.5B
Revenue:
$1.7B
EPS (TTM):
$7.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$289.2M | -$0.15 | -80.75% | -52.54% | $87.57 |
|
ARDX
Ardelyx, Inc.
|
$118M | $0.01 | 29.39% | -24.59% | $16.10 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 4.94% | 9.76% | $88.17 |
|
OVID
Ovid Therapeutics, Inc.
|
$62.6K | -$0.10 | -17.63% | -24.79% | $4.05 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -36.69% | -91.57% | $21.04 |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.80 | 315.28% | -9.26% | $58.57 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$68.19 | $87.57 | $5.5B | 8.81x | $0.00 | 0% | 3.27x |
|
ARDX
Ardelyx, Inc.
|
$6.55 | $16.10 | $1.6B | -- | $0.00 | 0% | 3.88x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.73 | $88.17 | $11.9B | 34.65x | $0.00 | 0% | 3.73x |
|
OVID
Ovid Therapeutics, Inc.
|
$1.63 | $4.05 | $116.1M | -- | $0.00 | 0% | 17.53x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$16.76 | $21.04 | $1.8B | 20.50x | $0.00 | 0% | 0.78x |
|
SYRE
Spyre Therapeutics, Inc.
|
$43.01 | $58.57 | $3.4B | -- | $0.00 | 0% | 701.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
206.17% | 0.479 | 6.54% | 2.21x |
|
ARDX
Ardelyx, Inc.
|
55.47% | -0.695 | 14.68% | 3.80x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
8.93% | -0.896 | 5.23% | 3.25x |
|
OVID
Ovid Therapeutics, Inc.
|
23.54% | 4.368 | 14.88% | 3.77x |
|
SRPT
Sarepta Therapeutics, Inc.
|
47.41% | -0.463 | 45.6% | 1.22x |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | 1.781 | -- | 12.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTCT
PTC Therapeutics, Inc.
|
$148.4M | -$81.6M | 2742.58% | -- | -49.57% | -$71.6M |
|
ARDX
Ardelyx, Inc.
|
$113.4M | $5.1M | -18.01% | -39.5% | 4.07% | $20.6M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$598.9M | $79.4M | 5.34% | 5.89% | 9.08% | $56.6M |
|
OVID
Ovid Therapeutics, Inc.
|
$115K | -$12.5M | -48.14% | -59.7% | -9487.12% | -$12.9M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$34.1M | -$410.1M | -32.9% | -64.94% | -92.58% | -$55.6M |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$57.2M | -25.86% | -25.86% | -- | -$44.6M |
PTC Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PTCT or ARDX?
Ardelyx, Inc. has a net margin of -81.96% compared to PTC Therapeutics, Inc.'s net margin of -0.33%. PTC Therapeutics, Inc.'s return on equity of -- beat Ardelyx, Inc.'s return on equity of -39.5%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M ARDXArdelyx, Inc.90.6% -$0.00 $374.9M -
What do Analysts Say About PTCT or ARDX?
PTC Therapeutics, Inc. has a consensus price target of $87.57, signalling upside risk potential of 28.42%. On the other hand Ardelyx, Inc. has an analysts' consensus of $16.10 which suggests that it could grow by 145.8%. Given that Ardelyx, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Ardelyx, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 4 1 ARDXArdelyx, Inc.10 0 0 -
Is PTCT or ARDX More Risky?
PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Ardelyx, Inc. has a beta of 0.570, suggesting its less volatile than the S&P 500 by 43.011%.
-
Which is a Better Dividend Stock PTCT or ARDX?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Ardelyx, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or ARDX?
PTC Therapeutics, Inc. quarterly revenues are $164.7M, which are larger than Ardelyx, Inc. quarterly revenues of $125.2M. PTC Therapeutics, Inc.'s net income of -$135M is lower than Ardelyx, Inc.'s net income of -$407K. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.81x while Ardelyx, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.27x versus 3.88x for Ardelyx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M ARDXArdelyx, Inc.3.88x -- $125.2M -$407K
-
Which has Higher Returns PTCT or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -81.96% compared to PTC Therapeutics, Inc.'s net margin of -5.33%. PTC Therapeutics, Inc.'s return on equity of -- beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M BMRNBioMarin Pharmaceutical, Inc.68.48% -$0.24 $6.7B -
What do Analysts Say About PTCT or BMRN?
PTC Therapeutics, Inc. has a consensus price target of $87.57, signalling upside risk potential of 28.42%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 4 1 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is PTCT or BMRN More Risky?
PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock PTCT or BMRN?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or BMRN?
PTC Therapeutics, Inc. quarterly revenues are $164.7M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. PTC Therapeutics, Inc.'s net income of -$135M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.81x while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.27x versus 3.73x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M BMRNBioMarin Pharmaceutical, Inc.3.73x 34.65x $874.6M -$46.6M
-
Which has Higher Returns PTCT or OVID?
Ovid Therapeutics, Inc. has a net margin of -81.96% compared to PTC Therapeutics, Inc.'s net margin of -9210.61%. PTC Therapeutics, Inc.'s return on equity of -- beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M OVIDOvid Therapeutics, Inc.87.12% -$0.17 $58.5M -
What do Analysts Say About PTCT or OVID?
PTC Therapeutics, Inc. has a consensus price target of $87.57, signalling upside risk potential of 28.42%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 148.41%. Given that Ovid Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 4 1 OVIDOvid Therapeutics, Inc.11 0 0 -
Is PTCT or OVID More Risky?
PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.621%.
-
Which is a Better Dividend Stock PTCT or OVID?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or OVID?
PTC Therapeutics, Inc. quarterly revenues are $164.7M, which are larger than Ovid Therapeutics, Inc. quarterly revenues of $132K. PTC Therapeutics, Inc.'s net income of -$135M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.81x while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.27x versus 17.53x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M OVIDOvid Therapeutics, Inc.17.53x -- $132K -$12.2M
-
Which has Higher Returns PTCT or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -81.96% compared to PTC Therapeutics, Inc.'s net margin of -93.07%. PTC Therapeutics, Inc.'s return on equity of -- beat Sarepta Therapeutics, Inc.'s return on equity of -64.94%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M SRPTSarepta Therapeutics, Inc.7.7% -$3.93 $2.2B -
What do Analysts Say About PTCT or SRPT?
PTC Therapeutics, Inc. has a consensus price target of $87.57, signalling upside risk potential of 28.42%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.04 which suggests that it could grow by 25.56%. Given that PTC Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 4 1 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is PTCT or SRPT More Risky?
PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock PTCT or SRPT?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or SRPT?
PTC Therapeutics, Inc. quarterly revenues are $164.7M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $442.9M. PTC Therapeutics, Inc.'s net income of -$135M is higher than Sarepta Therapeutics, Inc.'s net income of -$412.2M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.81x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.27x versus 0.78x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M SRPTSarepta Therapeutics, Inc.0.78x 20.50x $442.9M -$412.2M
-
Which has Higher Returns PTCT or SYRE?
Spyre Therapeutics, Inc. has a net margin of -81.96% compared to PTC Therapeutics, Inc.'s net margin of --. PTC Therapeutics, Inc.'s return on equity of -- beat Spyre Therapeutics, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital PTCTPTC Therapeutics, Inc.90.1% -$1.67 $193.4M SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M -
What do Analysts Say About PTCT or SYRE?
PTC Therapeutics, Inc. has a consensus price target of $87.57, signalling upside risk potential of 28.42%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $58.57 which suggests that it could grow by 36.18%. Given that Spyre Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Spyre Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTCTPTC Therapeutics, Inc.7 4 1 SYRESpyre Therapeutics, Inc.16 0 0 -
Is PTCT or SYRE More Risky?
PTC Therapeutics, Inc. has a beta of 0.484, which suggesting that the stock is 51.641% less volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 3.152, suggesting its more volatile than the S&P 500 by 215.196%.
-
Which is a Better Dividend Stock PTCT or SYRE?
PTC Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTCT or SYRE?
PTC Therapeutics, Inc. quarterly revenues are $164.7M, which are larger than Spyre Therapeutics, Inc. quarterly revenues of --. PTC Therapeutics, Inc.'s net income of -$135M is lower than Spyre Therapeutics, Inc.'s net income of -$51.8M. Notably, PTC Therapeutics, Inc.'s price-to-earnings ratio is 8.81x while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics, Inc. is 3.27x versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTCTPTC Therapeutics, Inc.3.27x 8.81x $164.7M -$135M SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
